-
1
-
-
0023113791
-
Osteoporosis in patients with inflammatory bowel disease
-
(1987)
Gut
, vol.28
, pp. 410-415
-
-
Compston, J.E.1
Judd, D.2
Crawely, E.O.3
Evans, W.D.4
Evans, C.5
Church, H.A.6
Reid, E.M.7
Rhodes, J.8
-
2
-
-
0028909280
-
Metabolic bone assessment in patients with inflammatory bowel disease
-
(1995)
Gastroenterology
, vol.108
, pp. 417-422
-
-
Abitbol, V.1
Roux, C.2
Chaussade, S.3
Guillemant, S.4
Kolta, S.5
Dougados, M.6
Couturier, D.7
Amor, B.8
-
12
-
-
18244431006
-
Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis
-
Glucocorticoid-Induced Osteoporosis Intervention Study Group
-
(1998)
N Engl J Med
, vol.339
, pp. 292-299
-
-
Saag, K.G.1
Emkey, R.2
Schnitzer, T.J.3
Brown, J.P.4
Hawkins, F.5
Goemaere, S.6
Thamsborg, G.7
Liberman, U.A.8
Delmas, P.D.9
Malice, M.P.10
Czachur, M.11
Daifotis, A.G.12
-
13
-
-
0028851590
-
Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis
-
The Alendronate Phase III Osteoporosis Treatment Study Group
-
(1995)
N Engl J Med
, vol.333
, pp. 1437-1443
-
-
Liberman, U.A.1
Weiss, S.R.2
Broll, J.3
Minne, H.W.4
Quan, H.5
Bell, N.H.6
Rodriguez Portales, J.7
Downs R.W., Jr.8
Dequeker, J.9
Favus, M.10
Seeman, E.11
Recker, R.R.12
Capizzi, T.13
Santora II, A.C.14
Lombardi, A.15
Shah, R.V.16
Hirsh, L.J.17
Karpf, D.B.18
-
14
-
-
0004851872
-
Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures
-
Fracture Intervention Trial Research Group
-
(1996)
Lancet
, vol.348
, pp. 1535-1541
-
-
Black, D.M.1
Cummings, S.R.2
Karpf, D.B.3
Cauley, J.A.4
Thompson, D.E.5
Nevitt, M.6
Bauer, D.C.7
Genant, H.K.8
Haskell, W.L.9
Marcus, R.10
Ott, S.M.11
Torner, J.C.12
Quandt, S.A.13
Reiss, T.F.14
Ensrud, K.E.15
-
16
-
-
85031606436
-
-
Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. WHO Technical Report Series, 843. Geneva, Switzerland: WHO
-
(1994)
-
-
-
19
-
-
0018758949
-
Measurement of circulating 1,25-dihydroxyvitamin D in man. Changes in serum concentrations during treatment with I alpha-hydroxycholecalciferol
-
(1979)
Acta Endocrinol Copenh
, vol.91
, pp. 338-350
-
-
Lund, B.1
Sorensen, O.H.2
-
20
-
-
0032583492
-
Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the Fracture Intervention Trial
-
(1998)
JAMA
, vol.280
, pp. 2077-2082
-
-
Cummings, S.R.1
Black, D.M.2
Thompson, D.E.3
Applegate, W.B.4
Barrett, C.E.5
Musliner, T.A.6
Palermo, L.7
Prineas, R.8
Rubin, S.M.9
Scott, J.C.10
Vogt, T.11
Wallace, R.12
Yates, A.J.13
LaCroix, A.Z.14
-
21
-
-
0029116697
-
Alendronate treatment of the post-menopausal osteoporotic woman: Effect of multiple dosages on bone mass and bone remodeling
-
(1995)
Am J Med
, vol.99
, pp. 144-152
-
-
Chesnut, C.H.1
McClung, M.R.2
Ensrud, K.E.3
Bell, N.H.4
Genant, H.K.5
Harris, S.T.6
Singer, F.R.7
Stock, J.L.8
Yood, R.A.9
Delmas, P.D.10
Kher, U.11
Pryor-Tillotson, S.12
Santora, A.C.S.13
-
22
-
-
9044249713
-
Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis
-
(1996)
Bone
, vol.18
, pp. 141-150
-
-
Devogelaer, J.P.1
Broll, H.2
Correa, R.R.3
Cumming, D.C.4
De, D.C.5
Geusens, P.6
Hosking, D.7
Jaeger, P.8
Kaufman, J.M.9
Leite, M.10
Leon, J.11
Liberman, U.12
Menkes, C.J.13
Meunier, P.J.14
Reid, I.15
Rodriguez, J.16
Romanowicz, A.17
Seeman, E.18
Vermeulen, A.19
Hirsch, L.J.20
Lombardi, A.21
Plezia, K.22
Santora, A.C.23
Yates, A.J.24
Yuan, W.25
more..
-
24
-
-
0029000389
-
Bone loss in patients with inflammatory bowel disease: A prospective study
-
(1995)
Osteoporos Int
, vol.5
, pp. 156-160
-
-
Roux, C.1
Abitbol, V.2
Chaussade, S.3
Kolta, S.4
Guillemant, S.5
Dougados, M.6
Amor, B.7
Couturier, D.8
-
25
-
-
0028802280
-
Studies of the oral bioavailability of alendronate
-
(1995)
Clin Pharmacol Ther
, vol.58
, pp. 288-298
-
-
Gertz, B.J.1
Holland, S.D.2
Kline, W.F.3
Matuszewski, B.K.4
Freeman, A.5
Quan, H.6
Lasseter, K.C.7
Mucklow, J.C.8
Porras, A.G.9
-
31
-
-
0028846051
-
Effects of oral alendronate and intranasal salmon calcitonin on bone mass and biochemical markers of bone turnover in postmenopausal women with osteoporosis
-
(1995)
Bone
, vol.17
, pp. 383-390
-
-
Adami, S.1
Passeri, M.2
Ortolani, S.3
Broggini, M.4
Carratelli, L.5
Caruso, I.6
Gandolini, G.7
Ganessi, L.8
Laurenzi, M.9
Lombardi, A.10
Norbiato, G.11
Pryor-Tilloston, S.12
Reda, C.13
Romanini, L.14
Subrizi, D.15
Wei, L.16
Yates, A.J.17
-
33
-
-
0010496839
-
Esophagitis associated with the use of alendronate
-
(1996)
N Engl J Med
, vol.335
, pp. 1016-1021
-
-
De Groen, P.C.1
Lubbe, D.F.2
Hirsch, L.J.3
Daifotis, A.4
Stephenson, W.5
Freedholm, D.6
Pryor Tillotson, S.7
Seleznick, M.J.8
Pinkas, H.9
Wang, K.K.10
-
36
-
-
0034066384
-
Guidelines for osteoporosis in coeliac disease and inflammatory bowel disease. British Society of Gastroenterology
-
(2000)
Gut
, vol.46
, Issue.SUPPL. 1
-
-
Scott, E.M.1
Gaywood, I.2
Scott, B.B.3
-
37
-
-
0029817443
-
A randomized, placebo-controlled trial of calcium supplementation for decreased bone density in corticosteroid-using patients with inflammatory bowel disease: A pilot study
-
(1996)
Aliment Pharmacol Ther
, vol.10
, pp. 777-786
-
-
Bernstein, C.N.1
Seeger, L.L.2
Anton, P.A.3
Artinian, L.4
Geffrey, S.5
Goodman, W.6
Belin, T.R.7
Shanahan, F.8
|